Ramesh Omranipour1,2, Roghiyeh Jalili1, Adel Yazdankhahkenary3, Abdolali Assarian4, Mehrzad Mirzania5, Bita Eslami1. 1. Breast Disease Research Center (BDRC), Tehran University of Medical Sciences, Tehran, Iran. 2. Department of Surgical Oncology, Cancer Institute, Tehran University of Medical Sciences, Tehran, Iran. 3. Trauma and Surgery Research Center, Sina hospital, Tehran University of Medical Sciences, Tehran, Iran. 4. Department of Surgery, Tehran University of Medical Sciences, Tehran, Iran. 5. Department of Hematology and Oncology, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, Iran.
Abstract
OBJECTIVE: The pathologic complete response (pCR) in the breast and axillary lymph node after neoadjuvant chemotherapy (NAC) would improve outcomes and it is used as a surrogate marker for survival. Our objective was to evaluate the breast and nodal pCR in breast cancer patients with estrogen receptor-positive (ER) and HER2 negative subtypes. Meanwhile, we sought to examine the impact of predicting factors on the rate of pCR. MATERIALS AND METHODS: In this multicenter retrospective study, medical records data of 314 women with ER+/HER2- breast cancer subtype who received neoadjuvant chemotherapy was extracted from oncology centers' data between 2011 and 2018. Breast and axillary lymph node pCR were assessed. Meanwhile, receiver operating characteristic (ROC) curve analysis was performed to assess the predictive value for proliferative index (Ki-67%) expression. RESULTS: Breast pCR was seen in 25.2% (n=79) of the 314 cancer patients and partial response was seen in 47.8% (n=150), too. Nodal pCR was reported in 30.9% (n=97) of the 249 node-positive patients. The overall pCR (both breast & node) was observed in 14.6 % (n=46) of the 272 patients in which the data of breast and nodal were available. We identified 22.5% as the best cut-off value for ki-67 expression in predicting complete response to NAC. CONCLUSION: The pCR rate after NAC in ER+/HER2- subtypes of breast cancer is low. Therefore, the optimal therapy for these patients should be further investigated.
OBJECTIVE: The pathologic complete response (pCR) in the breast and axillary lymph node after neoadjuvant chemotherapy (NAC) would improve outcomes and it is used as a surrogate marker for survival. Our objective was to evaluate the breast and nodal pCR in breast cancer patients with estrogen receptor-positive (ER) and HER2 negative subtypes. Meanwhile, we sought to examine the impact of predicting factors on the rate of pCR. MATERIALS AND METHODS: In this multicenter retrospective study, medical records data of 314 women with ER+/HER2- breast cancer subtype who received neoadjuvant chemotherapy was extracted from oncology centers' data between 2011 and 2018. Breast and axillary lymph node pCR were assessed. Meanwhile, receiver operating characteristic (ROC) curve analysis was performed to assess the predictive value for proliferative index (Ki-67%) expression. RESULTS: Breast pCR was seen in 25.2% (n=79) of the 314 cancer patients and partial response was seen in 47.8% (n=150), too. Nodal pCR was reported in 30.9% (n=97) of the 249 node-positive patients. The overall pCR (both breast & node) was observed in 14.6 % (n=46) of the 272 patients in which the data of breast and nodal were available. We identified 22.5% as the best cut-off value for ki-67 expression in predicting complete response to NAC. CONCLUSION: The pCR rate after NAC in ER+/HER2- subtypes of breast cancer is low. Therefore, the optimal therapy for these patients should be further investigated.
Authors: Marco Colleoni; Vincenzo Bagnardi; Nicole Rotmensz; Giuseppe Viale; Mauro Mastropasqua; Paolo Veronesi; Anna Cardillo; Rosalba Torrisi; Alberto Luini; Aron Goldhirsch Journal: Eur J Cancer Date: 2010-05-13 Impact factor: 9.162
Authors: Bryan T Hennessy; Gabriel N Hortobagyi; Roman Rouzier; Henry Kuerer; Nour Sneige; Aman U Buzdar; Shu Wan Kau; Bruno Fornage; Aysegul Sahin; Kristine Broglio; S Eva Singletary; Vicente Valero Journal: J Clin Oncol Date: 2005-12-20 Impact factor: 44.544
Authors: B Fisher; J Bryant; N Wolmark; E Mamounas; A Brown; E R Fisher; D L Wickerham; M Begovic; A DeCillis; A Robidoux; R G Margolese; A B Cruz; J L Hoehn; A W Lees; N V Dimitrov; H D Bear Journal: J Clin Oncol Date: 1998-08 Impact factor: 44.544
Authors: Judy C Boughey; Linda M McCall; Karla V Ballman; Elizabeth A Mittendorf; Gretchen M Ahrendt; Lee G Wilke; Bret Taback; A Marilyn Leitch; Teresa Flippo-Morton; Kelly K Hunt Journal: Ann Surg Date: 2014-10 Impact factor: 12.969
Authors: Waqar Haque; Vivek Verma; Sandra Hatch; V Suzanne Klimberg; E Brian Butler; Bin S Teh Journal: Breast Cancer Res Treat Date: 2018-04-24 Impact factor: 4.872
Authors: Peter A Fasching; Katharina Heusinger; Lothar Haeberle; Melitta Niklos; Alexander Hein; Christian M Bayer; Claudia Rauh; Ruediger Schulz-Wendtland; Mayada R Bani; Michael Schrauder; Laura Kahmann; Michael P Lux; Johanna D Strehl; Arndt Hartmann; Arno Dimmler; Matthias W Beckmann; David L Wachter Journal: BMC Cancer Date: 2011-11-14 Impact factor: 4.430
Authors: Matthew J Ellis; Vera J Suman; Jeremy Hoog; Rodrigo Goncalves; Souzan Sanati; Chad J Creighton; Katherine DeSchryver; Erika Crouch; Amy Brink; Mark Watson; Jingqin Luo; Yu Tao; Michael Barnes; Mitchell Dowsett; G Thomas Budd; Eric Winer; Paula Silverman; Laura Esserman; Lisa Carey; Cynthia X Ma; Gary Unzeitig; Timothy Pluard; Pat Whitworth; Gildy Babiera; J Michael Guenther; Zoneddy Dayao; David Ota; Marilyn Leitch; John A Olson; D Craig Allred; Kelly Hunt Journal: J Clin Oncol Date: 2017-01-03 Impact factor: 44.544